Álvaro Pinto· @dralvaropinto · X·· 15 小时前评分70
正文 · 原文
Ivonescimab as 1L treatment for IMDC fav-risk advanced ccRCC. Promising antitumor activity, ORR 57.1%, DCR 95.2%. Manageable safety profile, TRAEs G3-4 26.9% #ESMO26
17 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Álvaro Pinto · x.com